Clinical trials: Acute Coronary Syndromes
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Heart Failure, Congestive
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00328692
- Testing
- rolofylline
- Volunteers
- 932 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Coronary Syndrome
Safety Study of APD-791 With Aspirin and/or Clopidogrel
Evaluating safety and PK parameter of APD-791 when co-administered with aspirin and clopidogrel.
- Trial name
- TG1C (NCT02034292)
- Testing
- Clopidogrel, Aspirin, APD791
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Acute Myocardial Infarction, Acute Coronary Syndrome
Genetesis Accelerated Registry
Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood…
- Trial name
- GEAR (NCT05051228)
- Testing
- CardioFlux
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Genetesis Inc.
Acute Coronary Syndrome
OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study
To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.
- Trial name
- NCT03716102
- Testing
- PCI with implantation with DES
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Svelte Medical Systems, Inc.
Acute Coronary Syndrome, Acute Myocardial Infarction
Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
Thi is an observational, non interventional, cohort analysis by using administrative databases (drugs treatment, laboratory and diagnostic tests, specialist visits and hospitalizations) of Sicilia region to evaluate treatment…
- Trial name
- HEALTH-DB ACS (NCT01678339)
- Where
- Italy
- Sponsor
- AstraZeneca
Non-ST Elevation Acute Coronary Syndrome
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc…
- Trial name
- NSTE-ACS (NCT02052635)
- Testing
- ticagrelor, clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Thromboembolism
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of…
- Trial name
- NCT00064428
- Testing
- fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated
- Volunteers
- 12,092 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
ARCANGELO (itAlian pRospective Study on CANGrELOr)
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety…
- Trial name
- ARCANGELO (NCT04471870)
- Where
- 30 sites in Italy
- Volunteers
- 1,005 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Acute Coronary Syndrome
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers
A randomized, open-label, single dose, crossover study to evaluate pharmacokinetic profiles and safety/tolerability of CKD-357 in healthy volunteers
- Trial name
- NCT03671941
- Testing
- D578, CKD-357
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Heart Failure, Acute Decompensated Heart Failure
Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance
- Conditions
- Heart Failure, Acute Decompensated Heart Failure, Cardiorenal Syndrome, Heart Failure, Congestive
- Trial name
- NCT06174623
- Testing
- ModulHeart Support
- Where
- 5 sites in Australia, Georgia
- Volunteers
- 5 people
- Sponsor
- Puzzle Medical Devices Inc.
Acute Coronary Syndrome
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death…
- Trial name
- LIBREXIA-ACS (NCT05754957)
- Testing
- Milvexian
- Where
- 1,003 sites in United States, Argentina and 42 more
- Volunteers
- 14,194 people
- Sponsor
- Janssen Research & Development, LLC
Stable Coronary Artery Disease, Acute Coronary Syndromes
Coronary Laser Atherectomy Registry From an International Taskforce
This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).
- Trial name
- CLARIT (NCT07348341)
- Testing
- Excimer Laser Coronary Atherectomy (ELCA)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Ceric Sàrl
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndromes
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart…
- Trial name
- CLARITY-TIMI28 (NCT00714961)
- Testing
- Clopidogrel (SR25990)
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 3,491 people
- Sponsor
- Sanofi
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndromes
Drug Interaction Statin
This purpose of this study is to assess the effects of BMS-919373 on the single dose Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects.
- Trial name
- NCT02089061
- Testing
- BMS-919373, Rosuvastatin, Atorvastatin
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb